|
|
 | | | |
- close
- close
- close
- close
| |||||||||
Edwards Lifesciences 8-K 2007 UNITED STATES WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Date of report (Date of earliest event reported): September 17, 2007 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter)
(949) 250-2500 Registrant’s telephone number, including area code N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-Commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On September 17, 2007, the Board of Directors of Edwards Lifesciences Corporation (the “Company”) voted to amend the Company’s bylaws to provide for majority voting in uncontested director elections. A copy of the amended and restated Bylaws is attached as exhibit 3.2. Item 9.01. Financial Statements and Exhibits. (d) Exhibits 3.2 Bylaws of Edwards Lifesciences Corporation (amended and restated as of September 17, 2007). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
3 Exhibit Index
4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
